WASHINGTON — Although a greater number of patients with Crohn’s disease who failed anti-TNF therapy achieved biologic remission with Skyrizi vs. Stelara, choosing between the two therapies “still remains on the table,” a researcher noted.
Skyrizi (risankizumab, AbbVie) previously demonstrated noninferiority for clinical remission at week 24, and superior endoscopic
WASHINGTON — A blood-based screening test detected colorectal cancer with a sensitivity of 79.2% and a specificity of 91.5% among average-risk adults aged 45 to 85 years, according to research presented at Digestive Disease Week.
“Adherence to colon cancer screening tests is suboptimal with current options of stool-based tests and colonoscopy,” Aasma Shaukat, MD, MPH, director
WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.
“As a future gastroenterologist and current physician advocating for patients with obesity, my research team and I found a critical need to explore
WASHINGTON — Parental obesity was associated with a nearly threefold increased risk for metabolic dysfunction-associated steatotic liver disease among offspring in early adulthood, according to data presented at Digestive Disease Week.
“Notably, there are no widely adopted screening protocols to identify younger patients with MASLD, as the disease is largely silent and doesn’t
The WHO has announced the launch of SPECS 2030, a global initiative to assist countries in attaining a 40% increase in the proportion of people with access to appropriate spectacles.“The SPECS 2030 initiative marks a significant milestone in combatting uncorrected refractive error . which is the leading cause of vision impairment in both children and adults,” Bente Mikkelsen, MD,